Anteris Technologies Global Corp. · NASDAQ:AVR
Anteris Technologies Global — Technical Presentation (November 2023)
9 slides from Anteris Technologies Global's technical presentation, Nov 19, 2023
Slide 1: DurAVR Biomimetic Transcatheter Heart Valve: Results from the first-in-human and US early feasibility studies
DurAVR Biomimetic Transcatheter Heart Valve: Results from the first-in-human and US early feasibility studies Azeem Latib, MD Montefiore Medical Center, New York
Slide 2: Potential conflicts of interest
Potential conflicts of interest I have the following potential conflicts of interest to report: ❑ Consultant: Abbott; Medtronic; Edwards Lifesciences; Shifamed; Meacor; Supira; Boston Scientific Corporation; NeoChord ❑ Grant/Research Support: Medtronic; Edwards Lifesciences; Philips; Abbott; Boston
Slide 3: DurAVR A New Class of TAVR
DurAVR™ A New Class of TAVR Single-piece, native-shaped biomimetic design built to mimic the performance of a healthy aortic valve Caution: Investigational Device. Limited by Federal law to investigational use only. Exclusively for clinical investigations. PCRLondonValves.com
Slide 4: FIH and EFS Study Design and Baseline Characteristics
DurAVR™ FIH and EFS Study Design and Baseline Characteristics FIH EFS Study and Baseline characteristics Design n = 20 n = 15 1 7 Prospective, non-randomized, single- Number of Centers (Tbilisi, Georgia) (United States) arm studies to evaluate safety and Number of Subjects 20 15 feasibility of DurAV
Slide 5: Precise Placement and Excellent Safety Profile
Precise Placement and Excellent Safety Profile 100% Procedural Success Excellent Safety Profile FIH* EFS* n = 20 n = 15 1 non-cardiac Death 0 (car accident) Stroke 0 0 Minor or Major Bleeding 0 0 Reoperation or Reintervention 0 0 New Pacemaker Implantation 1# 1# * Average follow-up duration: FIH 309
Slide 6: Excellent Haemodynamic Results
DurAVR™ Excellent Haemodynamic Results Consistent Results through 1 Year Continued Haemodynamic Excellence First-in-Human Early Feasibility Study 53 41 2.4 2.1 2.0 2.0 2.0 MPG (mmHg) MPG (mmHg) EOA (cm2) EOA (cm2) Mean annulus: 22.7mm Mean annulus: 22.2mm 0.8 0.7 8.5 8.6 9.2 7.8 7.9 Baseline 30-days
Slide 7: Paradigm Shifting 30-day EFS Hemodynamic Results
Paradigm Shifting 30-day EFS Hemodynamic Results* Mean Annulus size: 22.2 mm EOA MPG DVI (Effective Orifice Area) (Mean Pressure Gradient) (Doppler Velocity Index) 2.13 7.9 0.62 cm2 mmHg No PVL reported at 30-day follow-up (30-day Follow-Up, n=12) *Echo Core Lab Analysis Caution: Investigational Dev
Slide 8: DurAVR A New Class of TAVR
DurAVR™ A New Class of TAVR DurAVR™ biomimetic valve has demonstrated outstanding haemodynamic performance in both the First-in-Human and Early Feasibility Studies Delivery System was intuitive and easy to use Both DurAVR™ First-in-Human and Early Feasibility Studies confirm excellent safety profile
Slide 9: PCRonline.com
PCR PCRonline.com
Anteris Technologies Global — Technical Presentation (November 2023) on 6ix